What features do Armis Centrix™ for VIPR vs Atera Network Discovery offer?

**Armis Centrix™ for VIPR** differentiates with Real-time medical device inventory and visibility, Vulnerability detection and deduplication, Clinical Impact Score for patient safety prioritization. **Atera Network Discovery** differentiates with NMAP-powered network device discovery and cataloging, CVE identification via open port scanning, Real-time alerts for newly connected or unauthorized devices.

Who makes Armis Centrix™ for VIPR vs Atera Network Discovery?

**Armis Centrix™ for VIPR** is developed by Armis. **Atera Network Discovery** is developed by Atera. Vendor maturity, funding stage, and team size can be important factors when evaluating long-term viability and support quality.

Is Armis Centrix™ for VIPR a good alternative to Atera Network Discovery?

Armis Centrix™ for VIPR and Atera Network Discovery serve similar Vulnerability Assessment use cases: both are Vulnerability Assessment tools. Review the feature comparison above to determine which fits your requirements.

Armis Centrix™ for VIPR vs Atera Network Discovery (2026) | Compare Vulnerability Assessment Tools

Q: What is the difference between Armis Centrix™ for VIPR vs Atera Network Discovery?

**Armis Centrix™ for VIPR**: Healthcare-focused vuln mgmt platform for medical device security & risk prioritization. built by Armis. headquartered in United States. Core capabilities include Real-time medical device inventory and visibility, Vulnerability detection and deduplication, Clinical Impact Score for patient safety prioritization.. **Atera Network Discovery**: RMM-integrated network scanner for device discovery, inventory, and CVE detection. built by Atera. headquartered in Israel. Core capabilities include NMAP-powered network device discovery and cataloging, CVE identification via open port scanning, Real-time alerts for newly connected or unauthorized devices.. Both serve the Vulnerability Assessment market but differ in approach, feature depth, and target audience.